Grand Rounds Nation®

Faculty: Mukul Sharma, MD, MSc, FRCPC

Faculty: Ashkan Shoamanesh, MD, MSc, FRCPC

Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn’t have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You’ll break down the science behind FXI, review key clinical trial data, and examine where these therapies may fit in secondary stroke prevention. Through real-world scenarios, discover how FXI inhibitors could help address residual stroke risk without the same bleeding concerns that limit current options.

Guest: Charles E. Miller, MD, FACOG

Whenever the topic of establishing minimally invasive hysteroscopic surgery in the office setting comes up, many physicians ask why and how. Leveraging decades of professional experience, this activity answers those questions by reviewing the necessary training and staff requirements, the procedures that are most beneficial for your patients, the path to accruing a patient and referral base, and most importantly, maintaining patient safety while ensuring pain control with optimal outcomes.

Guest: Cynthia Gyamfi-Bannerman, MD, BSc, MSc

About 30% of preterm labor spontaneously resolves and 50% of patients hospitalized for preterm labor actually give birth at term. Clinicians are left with the task to effectively assess women who are at risk for prenatal delivery in order to prevent preterm labor and reduce perinatal morbidity and mortality. In this activity, clinicians will learn practical strategies combining patient history, fetal fibronectin (fFN) levels, and ultrasonography imaging results to assess patient risks for preterm delivery, in order to provide adequate counseling regarding prenatal care and lifestyle changes.

To download the algorithms mentioned in this activity, click here.1

1. McCue, B, Torbenson, VE. Fetal fibronectin: The benefits of a high negative predictive value in management of preterm labor.Contemp Ob Gyn. 2017;62(10)(suppl):1-6

Guest: Sagar Lonial, MD, FACP

The treatment armamentarium for multiple myeloma (MM) has expanded significantly in recent years, with 6 new agents or indications approved by the US Food & Drug Administration since 2015. Treatment options now include immunomodulatory drugs, proteasome inhibitors, a histone deacetylase inhibitor, and immunotherapies, making clinical decisions much more complex. Additionally, best practices and consensus guidelines, such as those from the National Comprehensive Cancer Network® (NCCN®) and International Myeloma Working Group (IMWG), are constantly evolving as new data are published. Approval of these new agents, revision of response criteria, and implementation of new approaches to risk assessment and monitoring residual disease are causing significant changes in the management of MM.

This activity will review areas of current controversy and topics for which consensus is not yet established, including when to initiate treatment, determining transplant eligibility, high-risk disease, duration of maintenance therapy, sequencing newly approved drugs, and choice of treatment at relapse.

Guest: Scott Newsome, DO, MSCS, FAAN

The complexity and heterogeneity of multiple sclerosis (MS) pathogenesis renders its clinical course and response to therapy highly variable, particularly among special populations. This includes patients considering pregnancy or minority patients. This necessitates optimal strategies to personalize therapy and monitor disease activity and progression in special populations. This educational activity will review cutting-edge research on the unique considerations for prognosis, monitoring, and treatment response in special populations of MS patients. Focused attention will be given to translating research into optimized therapeutic strategies tailored to patient-specific characteristics with the goal of slowing disease progression. A compelling case study will be presented to illustrate clinically relevant challenges in disease management. Fee Information & Refund/Cancellation Policy:There is no fee for this educational activity. To download the slide handouts for this presentation, please click here.

Guest: Charles E. Miller, MD, FACOG

This Grand Round activity leverages decades of professional experience with minimally invasive hysteroscopic surgery (MIS) in the office setting. Learn the Why? and How? of establishing a successful in-office MIS practice, needed training and staff requirements, procedures most beneficial for your patients, the path to accruing a patient- and referral-base and, most important, maintaining patient safety while ensuring pain control with optimal outcome.

Guest: Martin R. Chavez, MD, FACOG

About 30% of preterm labor spontaneously resolves and 50% of patients hospitalized for preterm labor actually give birth at term. Clinicians are left with the task to effectively assess women who are at risk for prenatal delivery in order to prevent preterm labor and reduce perinatal morbidity and mortality. In this activity, clinicians will learn practical strategies combining patient history, fetal fibronectin (fFN) levels, and ultrasonography imaging results to assess patient risks for preterm delivery, in order to provide adequate counselling regarding prenatal care and lifestyle changes.

Discover how hearing loss in the US is growing and how it affects young and older people alike. Protect your patients' hearing with these tips and resources in an increasingly noisy world from Dr. John Iskander and Dr. William Murphy in this session of Beyond the Data.

Visit Dangerousdecibels.org to learn how to protect your hearing. Discover “How loud is too loud?”

Guest: Emma Guttman-Yassky, MD, PhD

Atopic dermatitis (AD) is the most common and relapsing allergic disease of the skin. Atopic dermatitis (or atopic eczema) is an inflammatory skin condition characterized by pruritis, and often occurring in the skin flexures. The prevalence rate for atopic dermatitis is estimated at up to 25% in children and 2%-3% adults. The diagnosis and management of patients with atopic dermatitis presents challenges along the course of the disease. New findings from scientific research as to the pathophysiology of AD is redefining strategies for its therapeutic management.

Guest: Donald Y. Leung, MD, PhD

Atopic dermatitis (AD) is the most common and relapsing allergic disease of the skin. Atopic dermatitis (or atopic eczema) is an inflammatory skin condition characterized by pruritis, and often occurring in the skin flexures. The prevalence rate for atopic dermatitis is estimated at up to 25% in children and 2%-3% adults. The diagnosis and management of patients with atopic dermatitis presents challenges along the course of the disease. New findings from scientific research as to the pathophysiology of AD is redefining strategies for its therapeutic management.